NASDAQ:ETON - Eton Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.57 -0.03 (-0.39 %) (As of 03/19/2019 11:45 AM ET)Previous Close$7.60Today's Range$7.50 - $7.5752-Week Range$5.70 - $8.11Volume3,337 shsAverage Volume54,141 shsMarket Capitalization$133.31 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company is developing DS-300, an injectable nutrition product candidate; EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-103, an oral liquid product candidate; DS-100, an injectable product candidate for use in pain management; DS-200, an injectable parenteral nutrition product candidate; ET-101, an oral liquid product for use in seizure control; ET-102, an oral liquid product for use as a muscle relaxant; and CT-100, a synthetic corticotropin therapeutic candidate that mimics the amino acid chain of H.P. Acthar Gel. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Receive ETON News and Ratings via Email Sign-up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETON Previous Symbol CUSIPN/A CIKN/A Webwww.etonpharma.com Phone847-787-7361Debt Debt-to-Equity RatioN/A Current Ratio5.71 Quick Ratio5.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares17,610,000Market Cap$133.31 million Next Earnings Date3/21/2019 (Estimated) OptionableNot Optionable Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions What is Eton Pharmaceuticals' stock symbol? Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON." How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals Inc (NASDAQ:ETON) issued its quarterly earnings data on Thursday, December, 20th. The company reported ($0.65) earnings per share (EPS) for the quarter. View Eton Pharmaceuticals' Earnings History. When is Eton Pharmaceuticals' next earnings date? Eton Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Eton Pharmaceuticals. Has Eton Pharmaceuticals been receiving favorable news coverage? News headlines about ETON stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eton Pharmaceuticals earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Eton Pharmaceuticals' key competitors? Some companies that are related to Eton Pharmaceuticals include Urogen Pharma (URGN), DiaMedica Therapeutics (DMCAF), ArQule (ARQL), Arcus Biosciences (RCUS), ChemoCentryx (CCXI), NuCana (NCNA), Dynavax Technologies (DVAX), BioSpecifics Technologies (BSTC), Assembly Biosciences (ASMB), Emisphere Technologies (EMIS), Zymeworks (ZYME), CytomX Therapeutics (CTMX), ZEALAND PHARMA/S (ZEAL), Akebia Therapeutics (AKBA) and Corium International (CORI). What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Yangarra Resources (YGR), ConvergeOne (CVON), Second Sight Medical Products (EYES), AFLAC (AFL), Synergy Pharmaceuticals (SGYP), PDL BioPharma (PDLI), Donnelley Financial Solutions (DFIN), Tellurian (TELL), Bristol-Myers Squibb (BMY) and Mimecast (MIME). Who are Eton Pharmaceuticals' key executives? Eton Pharmaceuticals' management team includes the folowing people: Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 47)Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 64) When did Eton Pharmaceuticals IPO? (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. When does the company's lock-up period expire? Eton Pharmaceuticals' lock-up period expires on Monday, May 13th. Eton Pharmaceuticals had issued 3,600,000 shares in its IPO on November 13th. The total size of the offering was $21,600,000 based on an initial share price of $6.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (2.97%) and Apollo Management Holdings L.P. (0.51%). Company insiders that own Eton Pharmaceuticals stock include Sean Brynjelsen and William Wilson Troutman. View Institutional Ownership Trends for Eton Pharmaceuticals. Which institutional investors are buying Eton Pharmaceuticals stock? ETON stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and Apollo Management Holdings L.P.. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Sean Brynjelsen and William Wilson Troutman. View Insider Buying and Selling for Eton Pharmaceuticals. How do I buy shares of Eton Pharmaceuticals? Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eton Pharmaceuticals' stock price today? One share of ETON stock can currently be purchased for approximately $7.57. How big of a company is Eton Pharmaceuticals? Eton Pharmaceuticals has a market capitalization of $133.31 million. What is Eton Pharmaceuticals' official website? The official website for Eton Pharmaceuticals is http://www.etonpharma.com. How can I contact Eton Pharmaceuticals? Eton Pharmaceuticals' mailing address is 21925 W. Field Parkway Suite 235, Deer Park IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected] MarketBeat Community Rating for Eton Pharmaceuticals (NASDAQ ETON)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 24 (Vote Outperform)Underperform Votes: 32 (Vote Underperform)Total Votes: 56MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote "Outperform" if you believe ETON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is the Difference Between Common Shares and Convertible Shares?